Cases of low-grade B-cell lymphoma presenting primarily in the bone marrow are rare, and its clinicopathology remains unclear. We retrospectively examined patients with low-grade B-cell lymphoma presenting primarily in the bone marrow. Fourteen patients met the inclusion criteria, including 5 with lymphoplasmacytic lymphoma (LPL), 3 with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 2 with follicular lymphoma (FL), and 4 with low-grade B-cell lymphoma not otherwise specified (LGBCL-NOS). The median age was 69.5 years (range, 42-89 years), and a slight male predominance was noted (9 men and 5 women, 1.8: 1).
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frequently occurs at the duodenum and spreads to the small intestine, and primary cutaneous follicle center lymphoma is localized to the skin and exhibits an indolent clinical course.
Low-grade B-cell lymphomas such as FL, lymphoplasmacytic lymphoma (LPL),
and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) frequently involve the bone marrow [1] [2] [3] [4] [5] . However, cases of low-grade B-cell lymphoma presenting primarily in the bone marrow are quite rare. Only one report [6] concerning primary bone marrow lymphoma has investigated this issue; however, the authors included aggressive B-cell lymphomas such as diffuse large B-cell lymphoma in the inclusion criteria. Therefore, the clinicopathological features and clinical behavior of low-grade B-cell lymphomas presenting primarily in the bone marrow are still unknown.
In the present study, we retrospectively analyzed a series of 14 patients with low-grade B-cell lymphoma presenting primarily in the bone marrow and attempted to clarify the
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clinicopathological and genotypic characteristics.
MATERIALS AND METHODS

Patient selection
The pathology database at our institution was searched for cases of low-grade B-cell A total of 14 patients met the inclusion criteria. Of the 14 patients, bone marrow biopsy findings were available in 7 patients and clot section findings were available in the other 7 patients. The major differential diagnostic points between CLL/SLL and
LGBCL-NOS are described as follows. First, clinically, the patients who had elevated white blood cell counts generally had CLL/SLL; these cases were excluded for the LGBCL-NOS" for cases that did not meet any WHO criteria, because they could not be further subtyped. Bone marrow aspirate cytology was available in 12 patients. Other clinical data were collected, including blood cell counts, serum biochemistry, including the levels of lactate dehydrogenase (LDH), soluble interleukin 2 receptor (sIL2-R), and M protein type. Survival outcomes were also examined. The invasion pattern of the bone marrow was evaluated according to the criteria proposed by Arber et al. [1] . The study protocol was approved by the Institutional Review Board of Okayama University, Okayama, Japan, and written informed consent was obtained from each patient. All study procedures were conducted in accordance with the guidelines of the Declaration
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of Helsinki.
Flow cytometric analysis
Flow cytometric analysis was performed on 13 samples obtained from either bone marrow aspirates or peripheral blood using a single-tube, 2-color method as described previously [10] . Monoclonal antibodies against CD3, CD5, CD10, CD19, CD20, CD23, CD38, CD45, and Igκ and Igλ light chains were used. The data were acquired on a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using CellQuest software (BD Biosciences, San Jose, CA, USA).
Immunohistochemistry and in situ hybridization
Immunohistochemical analysis was performed on 10% formalin-fixed, exhibited >30% positivity for MUM1. Furthermore, the Ki-67 index was determined; it was considered low and high at <10% and >10%, respectively. Fluorescence in situ hybridization (FISH) analysis for immunoglobulin heavy locus (IgH)/BCL-2 rearrangement t(14;18) was performed using a commercially available FISH probe set (Abbott Molecular Inc., Wiesbaden, Germany) [12] on paraffin blocks available from patients #9-14. FISH analysis for API2/MALT1 t(11; 18)(q21; q21) was also performed for LPL and LGBCL-NOS patients using a commercially available FISH probe set
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(Abbott Molecular Inc., Des Plaines, IL, USA) [13] . FISH analysis for IRF4 gene translocation was also performed for immunohistochemically MUM1-positive samples using a commercially available FISH probe set (KREATECH, Amsterdam, The Netherlands) [14] .
Screening for the myeloid differentiation primary response gene (88) (MYD88) L265P mutations
DNA was isolated from formalin-fixed paraffin-embedded tissue using the QIAmp system (Qiagen). MYD88 genes were amplified by polymerase chain reaction (PCR).
The forward and reverse primers were used for MYD88 were 5′-GTTGAAGACTGGGCTTGTCC-3′ and 5′-GTGCAGGGGTTGGTGTAGTC-3′, respectively. The purified PCR products were directly sequenced in both directions using the BigDye Terminator Cycle Sequencing Kit and analyzed on an automatic 3500 DNA sequencer (Applied Biosystems).
IgVH sequence analysis
Immunoglobulin heavy chain gene rearrangement was detected by PCR. DNA was extracted from formalin-fixed paraffin-embedded tissue sections. Immunoglobulin
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heavy chain genes were amplified by using semi-nested PCR, with the primers directed to the framework 2 region (FR2A: 5′-TGGRTCCGMCAGSCYYCNGG-3′ for both the first and second PCR) and the joining region (LJH: 5′-TGAGGAGACGGTGACC-3′ for the first PCR, and VLJH: 5′-GTGACCAGGGTNCCTTGGCCCCAG-3′ for the second PCR). DNA samples were separately subjected to PCR with TAKARA Ex Taq (Takara Bio Inc., Otsu, Japan). The amplified products were electrophoresed on a 3% agarose gel. A product was determined to be "clonal" if a single or dominant discrete band was apparent. To sequence clonal bands, the PCR products were purified with ExoSAP-IT (USB, Affymetrix). Sequencing was performed using the BigDye Terminator version 3.1 Cycle Sequencing Kit (AB, Warrington, UK), and the reaction products were analyzed on an automatic 3130xl DNA sequencer (Applied Biosystems). The nucleotide sequences of VH regions were compared to deposited sequences using the IgBLAST database (http://www.ncbi.nlm.nih.gov/igblast/) in the PubMed Center.
RESULTS
Clinical manifestations and outcomes
The patients' clinical characteristics are summarized in Table 1 LGBCL-NOS patients had IgG.
Chemotherapy was performed in 9 of 14 patients. Among them, 7 patients received rituximab-containing therapy.
Three patients (#1, 2, and 8) died after 71, 83, and 62 months, respectively, with a median follow-up time of 36.5 months (range, 5-90 months): 2 patients had LPL (#1 and 2) and the other patient had CLL/SLL (#8). One LPL patient (#1) died because of intestinal hemorrhage, which was probably caused by thrombocytopenia. The other LPL patient (#2) died because of primary disease. One CLL/SLL patient (#8) died because of cerebral infarction.
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Pathological findings and FISH results
Among 14 patients with low-grade B-cell lymphoma localized to the bone marrow, 5, 3, 2, and 4 patients had LPL, CLL/SLL, FL, and LGBCL-NOS, respectively. The histologic and immunophenotypic features are summarized in Table 2 , Figure 1 , and
In LPL patients, the tumor cells exhibited diffuse proliferation and included smallto medium-sized lymphocytes, plasmacytoid lymphocytes, and plasma cells (Figure 2A ).
The bone marrow invasion pattern was evaluated in 3 patients, which included mixed paratrabecular and interstitial, mixed nodular and interstitial, and interstitial patterns, respectively. With regard to immunohistochemistry, 5 samples were CD20 positive, CD19 positive, and CD138 negative, whereas 1 was CD5 positive. In CLL/SLL samples, the tumor cells consisted mainly of small monotonous lymphocytes with round nuclear contours; in addition, paraimmunoblast clusters were observed ( Figure 2F ).
Immunohistochemical analysis revealed that all 3 were CD20 positive. In addition, all samples were positive for CD5 and CD23, as determined by flow cytometric analysis and/or immunohistochemical analysis. In 2 FL patients, tumor cells showed a diffuse or mixed nodular and interstitial pattern of invasion, and tumor follicles were not observed
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in either specimen. Tumor cells consisted of centrocytic cells admixed with some centroblastic cells ( Figure 2K ). Both samples were CD20, CD10 (#10 was partial), and BCL-2 positive according to immunohistochemical analysis. Follicular dendritic cells
were not detected by CD21 immunostaining. The FISH study demonstrated IGH-BCL2
translocations.
As a consequence of the exclusion criteria, 4 patients were classified as
LGBCL-NOS. No patients had elevated WBC counts or IgM paraproteinemia. In all 4
bone marrow specimens, small-to medium-sized monotonous cells with condensed nuclear chromatin were observed without plasma cells, plasmacytoid lymphocytes, or paraimmunoblast clusters. In 2 patients, the pattern of bone marrow invasion was evaluated, which included mixed interstitial and diffuse, and diffuse patterns.
Immunohistochemical analysis showed that all 4 samples were CD20 positive. One patient (#14) was partially positive for CD10 and CD138. This patient's sample was positive for CD19 and negative for Cyclin D1. The samples of 2 of 4 LGBCL-NOS patients were positive for CD23.
There were no IGH-BCL2 translocations in any of the 4 LGBCL-NOS patients according to the FISH study. Furthermore, the FISH study showed that there were no
API2-MALT1 translocations in LPL or LGBCL-NOS patients (data not shown). In
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addition, there were no IRF4 rearrangements in MUM1-positive patients (#8, #12, and #14; data not shown).
MYD88 L265P mutation and IgVH gene usage analysis
The MYD88 L265P mutation was found in 6 of 14 patients including 3 of 5 LPL, 1 of 2 FL, and 2 of 4 LGBCL-NOS patients. The MYD88 L265P mutation was not found in any of the CLL/SLL patients (Table 2 and Figure 3 ). VH usage was VH3-23, VH1-3, and VH4-34 in 3 CLL/SLL patients; VH3-7 and VH4-34 in 2 FL patients; and VH3-66
and VH4-59 in 2 LGBCL-NOS patients.
DISCUSSION
The present study analyzed different subtypes of low-grade B-cell lymphoma localized to the bone marrow, including LPL, CLL/SLL, FL, and LGBCL-NOS.
Torlakovic et al. [15] reported that paratrabecular and mixed paratrabecular patterns are common in FL. Moreover, interstitial and mixed interstitial patterns are common in LPL [1] . However, bone marrow invasion patterns vary in the other types of low-grade B-cell lymphomas [1] . In the present study, paratrabecular, nodular, interstitial, and diffuse
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
patterns were all observed. However, the cases of low-grade B-cell lymphoma did not exhibit any specific pattern. Moreover, none of the samples exhibited an intra-sinusoidal pattern.
FL generally occurs in the lymph nodes and rarely in the gastrointestinal tract. After excluding other sites of involvement, only 2 patients met the diagnostic criteria for FL.
Martinez et al. In the present study, the MYD88 L265P mutation was found in 3 of 5 LPL patients, 1 of 2 FL patients, and 2 of 4 LGBCL-NOS patients. Thus, the present results suggest that some LGBCL-NOS cases may share characteristics with LPL or marginal zone B-cell lymphoma. Nevertheless, it remains unclear whether LGBCL-NOS patients with the
MYD88 L265P mutation should be diagnosed with LPL. Therefore, further study is required to resolve this issue. However, patients with IgM paraproteinemia and LPL histology may be distinguished from those with LGBCL-NOS.
Among all patients analyzed, 3 died. One patient died of malignant lymphoma, whereas another patient died of intestinal hemorrhage, which was probably caused by severe thrombocytopenia. Thus, the cause of death was not only malignant lymphoma but also involved cytopenia or therapy. Therefore, the prognosis of low-grade B-cell lymphoma localized to the bone marrow should be studied further.
In conclusion, several subtypes of primary bone marrow lymphoma were identified in primary bone marrow lymphoma. Approximately one-third of patients with primary bone marrow lymphoma were classified as LGBCL-NOS, and shared clinicopathological and genotypic characteristics with LPL or marginal zone B-cell lymphoma. As the present study involved a relatively small sample size, additional studies with larger sample sizes are required to clarify the pathophysiology and prognosis of this disease. A C C E P T E D M A N U S C R I P T 9  FL  DIFF  100%  +  --+  +  --+  ----low  +  +   10  FL  NOD, INT  70%  +  --+  +  --+  -+  --low  +  -11  LGBCL-NOS  ND  100%  +  ---ND  p+  -+  ----low  UD  +   12  LGBCL-NOS  ND  80%  +  ---ND  --+  --+  -low  --13  LGBCL-NOS  INT, DIFF  90%  +  ---ND  --UD  ----low  UD  -14 LGBCL-NOS DIFF 100% + --p+ + + -+ p+ -+ -low -+ *positive based on flow cytometric analysis.
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CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DIFF, diffuse; FL, follicular lymphoma; INT, interstitial; LGBCL-NOS, low-grade B-cell lymphoma not otherwise specified; LPL, lymphoplasmacytic lymphoma; ND, not done; NOD, nodular; p+, partially positive; PT, paratrabecular; UD, undetermined
